Related Experiment Videos
The super anti-apoptotic factor Bcl-xFNK constructed by disturbing intramolecular polar interactions in rat Bcl-xL
1Department of Biochemistry and Cell Biology, Institute of Gerontology, Nippon Medical School, 1-396, Kosugi-cho, Nakahara-ku, Kawasaki-city, Kanagawa-ken 211-8533, Japan.
Abstract:
A powerful artificial anti-apoptotic factor will be useful for medical applications of the future therapies for many diseases by prolonging survival of sick cells. For constructing it, we designed the super anti-apoptotic factor by disturbing three intramolecular polar interactions among alpha-helix structures of Bcl-x(L). The resultant mutant Bcl-x(L), named Bcl-xFNK, was expected to make the pore-forming domain more mobile and flexible than the wild-type. When overexpressed in Jurkat cells, Bcl-xFNK was markedly more potent in prolonging survival following apoptosis-inducing treatment with a kind of cell death cytokines (anti-Fas), a protein kinase inhibitor (staurosporine), cell cycle inhibitors (TN-16, camptothecin, hydroxyurea, and trichostatin A), or oxidative stress (hydrogen peroxide and paraquat) than wild-type Bcl-x(L). Furthermore, the transfectants of bcl-xFNK became more resistant against a calcium ionophore and even a heat treatment than wild-type Bcl-x(L). In addition, Bcl-xFNK showed marked anti-apoptotic activity in Chinese hamster ovary and Jurkat cells deprived of serum. Thus, Bcl-xFNK may be the first mutant generated by site-directed mutagenesis of Bcl-x(L) with a gain-of-function phenotype. Interestingly, Bcl-xFNK was found to allow interleukin-3-dependent FDC-P1 to grow without interleukin-3, but not BaF/3. In Bcl-xFNK transfectants of FDC-P1 and Jurkat, the p42/p44 mitogen-activated protein kinase was activated by 2 to 5 times, but not in those of BaF/3 and Chinese hamster ovary. Bcl-xFNK might gain a new function to activate the mitogen-activated protein kinase in a cell-type specific manner. The findings of this study suggest that the central alpha5-alpha6 pore-forming region of anti-apoptotic factor Bcl-x(L) has a pivotal role in suppressing apoptosis.
Insights
Scientists engineered a super anti-apoptotic factor, Bcl-xFNK, by altering Bcl-x(L) protein structure. This novel mutant enhances cell survival against various apoptosis-inducing conditions, offering potential for future medical therapies.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Apoptosis, or programmed cell death, is crucial for development and disease.
- Bcl-x(L) is a key anti-apoptotic protein regulating cell survival.
- Developing artificial anti-apoptotic factors could advance future medical therapies.
Purpose of the Study:
- To engineer a super anti-apoptotic factor by modifying Bcl-x(L).
- To investigate the anti-apoptotic potency and potential new functions of the engineered mutant, Bcl-xFNK.
- To identify key structural regions of Bcl-x(L) involved in apoptosis suppression.
Main Methods:
- Site-directed mutagenesis was used to create the Bcl-xFNK mutant by disturbing intramolecular polar interactions in Bcl-x(L).
- Overexpression of Bcl-xFNK in various cell lines (Jurkat, Chinese hamster ovary, FDC-P1, BaF/3).
- Assays to assess cell survival following apoptosis induction (cytokines, inhibitors, oxidative stress, calcium ionophore, heat, serum deprivation) and to measure mitogen-activated protein kinase (MAPK) activation.
Main Results:
- The Bcl-xFNK mutant exhibited significantly enhanced anti-apoptotic activity compared to wild-type Bcl-x(L) across multiple cell types and apoptosis-inducing stimuli.
- Bcl-xFNK conferred resistance to calcium ionophore and heat treatment, and prolonged survival in serum-deprived conditions.
- Bcl-xFNK induced interleukin-3-independent growth in FDC-P1 cells and activated p42/p44 MAPK in a cell-type specific manner.
Conclusions:
- Bcl-xFNK is a novel Bcl-x(L) mutant with a gain-of-function phenotype, demonstrating superior anti-apoptotic capabilities.
- The study suggests the central alpha5-alpha6 pore-forming region of Bcl-x(L) is critical for its anti-apoptotic function.
- Bcl-xFNK may possess a new cell-type specific function involving MAPK activation, with implications for therapeutic development.